Rethinking the Viability and Utility of Inhaled Insulin in Clinical Practice

Overview

Journal J Diabetes Res

Publisher Wiley

Specialty Endocrinology

Date 2018 May 1

PMID 29707584

Citations 10

Authors

Lutz Heinemann

Christopher G Parkin

Affiliations

Soon will be listed here.

Abstract

Despite considerable advances in pharmacotherapy and self-monitoring technologies in the last decades, a large percentage of adults with diabetes remain unsuccessful in achieving optimal glucose due to suboptimal medication adherence. Contributors to suboptimal adherence to insulin treatment include pain, inconvenience, and regimen complexity; however, a key driver is hypoglycemia. Improvements in the PK/PD characteristics of today's SC insulins provide more physiologic coverage of basal and prandial insulin requirements than regular human insulin; however, they do not achieve the rapid on/rapid off characteristics of endogenously secreted insulin seen in healthy, nondiabetic individuals. Pulmonary administration of prandial insulin represents an attractive option that overcomes limitations of SC insulin by providing more a rapid onset of action and a faster return of action to baseline levels than SC administration of rapid-acting insulin analogs. This article reviews the unique PK/PD properties of a novel inhaled formulation that support its use in patient populations with T1D or T2D.

Citing Articles

A Randomized Trial Comparing Inhaled Insulin Plus Basal Insulin Versus Usual Care in Adults With Type 1 Diabetes.

Hirsch I, Beck R, Marak M, Kudva Y, Akturk H, Bhargava A Diabetes Care. 2024; 48(3):353-360.

PMID: 39641970 PMC: 11870290. DOI: 10.2337/dc24-1832.

A Randomized Comparison of Postprandial Glucose Excursion Using Inhaled Insulin Versus Rapid-Acting Analog Insulin in Adults With Type 1 Diabetes Using Multiple Daily Injections of Insulin or Automated Insulin Delivery.

Hirsch I, Beck R, Marak M, Calhoun P, Mottalib A, Salhin A Diabetes Care. 2024; 47(9):1682-1687.

PMID: 39042575 PMC: 11362108. DOI: 10.2337/dc24-0838.

Inhalable cardiac targeting peptide modified nanomedicine prevents pressure overload heart failure in male mice.

Weng H, Zou W, Tian F, Xie H, Liu A, Liu W Nat Commun. 2024; 15(1):6058.

PMID: 39025877 PMC: 11258261. DOI: 10.1038/s41467-024-50312-1.

Liposomes or Extracellular Vesicles: A Comprehensive Comparison of Both Lipid Bilayer Vesicles for Pulmonary Drug Delivery.

Al-Jipouri A, Almurisi S, Al-Japairai K, Bakar L, Doolaanea A Polymers (Basel). 2023; 15(2).

PMID: 36679199 PMC: 9866119. DOI: 10.3390/polym15020318.

Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Davies M, Aroda V, Collins B, Gabbay R, Green J, Maruthur N Diabetologia. 2022; 65(12):1925-1966.

PMID: 36151309 PMC: 9510507. DOI: 10.1007/s00125-022-05787-2.

References

Jin J, Sklar G, Oh V, Li S . Factors affecting therapeutic compliance: A review from the patient's perspective. Ther Clin Risk Manag. 2008; 4(1):269-86. PMC: 2503662. DOI: 10.2147/tcrm.s1458. View

Haugstvedt A, Wentzel-Larsen T, Graue M, Sovik O, Rokne B . Fear of hypoglycaemia in mothers and fathers of children with Type 1 diabetes is associated with poor glycaemic control and parental emotional distress: a population-based study. Diabet Med. 2010; 27(1):72-8. DOI: 10.1111/j.1464-5491.2009.02867.x. View

Miller K, Foster N, Beck R, Bergenstal R, DuBose S, DiMeglio L . Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care. 2015; 38(6):971-8. DOI: 10.2337/dc15-0078. View

Sokol M, McGuigan K, Verbrugge R, Epstein R . Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005; 43(6):521-30. DOI: 10.1097/01.mlr.0000163641.86870.af. View

Rave K, Heise T, Heinemann L, Boss A . Inhaled Technosphere insulin in comparison to subcutaneous regular human insulin: time action profile and variability in subjects with type 2 diabetes. J Diabetes Sci Technol. 2009; 2(2):205-12. PMC: 2771503. DOI: 10.1177/193229680800200206. View

Dandona P, Chaudhuri A, Ghanim H, Mohanty P . Proinflammatory effects of glucose and anti-inflammatory effect of insulin: relevance to cardiovascular disease. Am J Cardiol. 2007; 99(4A):15B-26B. DOI: 10.1016/j.amjcard.2006.11.003. View

Potocka E, Cassidy J, Haworth P, Heuman D, van Marle S, Baughman Jr R . Pharmacokinetic characterization of the novel pulmonary delivery excipient fumaryl diketopiperazine. J Diabetes Sci Technol. 2010; 4(5):1164-73. PMC: 2956823. DOI: 10.1177/193229681000400515. View

Brown J, Nichols G . Slow response to loss of glycemic control in type 2 diabetes mellitus. Am J Manag Care. 2003; 9(3):213-7. View

. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007; 50(6):1140-7. DOI: 10.1007/s00125-007-0599-y. View

10.

Levin P, Heinemann L, Boss A, Rosenblit P . Impact of symptomatic upper respiratory tract infections on insulin absorption and action of Technosphere inhaled insulin. BMJ Open Diabetes Res Care. 2016; 4(1):e000228. PMC: 5013402. DOI: 10.1136/bmjdrc-2016-000228. View

11.

Grant R, Buse J, Meigs J . Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. Diabetes Care. 2005; 28(2):337-442. PMC: 3829636. DOI: 10.2337/diacare.28.2.337. View

12.

Ilkova H, Glaser B, Tunckale A, Bagriacik N, Cerasi E . Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care. 1997; 20(9):1353-6. DOI: 10.2337/diacare.20.9.1353. View

13.

Angelo R, Rousseau K, Grant M, Leone-Bay A, Richardson P . Technosphere insulin: defining the role of Technosphere particles at the cellular level. J Diabetes Sci Technol. 2010; 3(3):545-54. PMC: 2769873. DOI: 10.1177/193229680900300320. View

14.

Lundkvist J, Berne C, Bolinder B, Jonsson L . The economic and quality of life impact of hypoglycemia. Eur J Health Econ. 2005; 6(3):197-202. DOI: 10.1007/s10198-005-0276-3. View

15.

Wild D, von Maltzahn R, Brohan E, Christensen T, Clauson P, Gonder-Frederick L . A critical review of the literature on fear of hypoglycemia in diabetes: Implications for diabetes management and patient education. Patient Educ Couns. 2007; 68(1):10-5. DOI: 10.1016/j.pec.2007.05.003. View

16.

Cariou B, Fontaine P, Eschwege E, Lievre M, Gouet D, Huet D . Frequency and predictors of confirmed hypoglycaemia in type 1 and insulin-treated type 2 diabetes mellitus patients in a real-life setting: results from the DIALOG study. Diabetes Metab. 2014; 41(2):116-25. DOI: 10.1016/j.diabet.2014.10.007. View

17.

Lingvay I, Legendre J, Kaloyanova P, Zhang S, Adams-Huet B, Raskin P . Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better?. Diabetes Care. 2009; 32(10):1789-95. PMC: 2752924. DOI: 10.2337/dc09-0653. View

18.

Cryer P . Hypoglycemia: still the limiting factor in the glycemic management of diabetes. Endocr Pract. 2008; 14(6):750-6. DOI: 10.4158/EP.14.6.750. View

19.

Siekmeier R, Scheuch G . Inhaled insulin--does it become reality?. J Physiol Pharmacol. 2009; 59 Suppl 6:81-113. View

20.

Ho P, Rumsfeld J, Masoudi F, McClure D, Plomondon M, Steiner J . Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006; 166(17):1836-41. DOI: 10.1001/archinte.166.17.1836. View